Lysophosphatidic acid enhances stromal cell-directed angiogenesis

Bernard Y K Binder, Claus S. Sondergaard, Jan Nolta, Jonathan K Leach

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Ischemic diseases such as peripheral vascular disease (PVD) affect more than 15% of the general population and in severe cases result in ulcers, necrosis, and limb loss. While the therapeutic delivery of growth factors to promote angiogenesis has been widely investigated, large-scale implementation is limited by strategies to effectively deliver costly recombinant proteins. Multipotent adipose-derived stromal cells (ASC) and progenitor cells from other tissue compartments secrete bioactive concentrations of angiogenic molecules, making cell-based strategies for in situ delivery of angiogenic cytokines an exciting alternative to the use of recombinant proteins. Here, we show that the phospholipid lysophosphatidic acid (LPA) synergistically improves the proangiogenic effects of ASC in ischemia. We found that LPA upregulates angiogenic growth factor production by ASC under two- and three-dimensional in vitro models of serum deprivation and hypoxia (SD/H), and that these factors significantly enhance endothelial cell migration. The concurrent delivery of LPA and ASC in fibrin gels significantly improves vascularization in a murine critical hindlimb ischemia model compared to LPA or ASC alone, thus exhibiting the translational potential of this method. Furthermore, these results are achieved using an inexpensive lipid molecule, which is orders-of-magnitude less costly than recombinant growth factors that are under investigation for similar use. Our results demonstrate a novel strategy for enhancing cell-based strategies for therapeutic angiogenesis, with significant applications for treating ischemic diseases.

Original languageEnglish (US)
Article numbere82134
JournalPLoS One
Volume8
Issue number12
DOIs
StatePublished - Dec 2 2013

Fingerprint

stromal cells
Stromal Cells
angiogenesis
Intercellular Signaling Peptides and Proteins
acids
growth factors
Recombinant Proteins
ischemia
recombinant proteins
Ischemia
Molecules
Endothelial cells
Fibrin
therapeutics
vascular diseases
fibrin
Peripheral Vascular Diseases
Angiogenesis Inducing Agents
production economics
Phospholipids

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Lysophosphatidic acid enhances stromal cell-directed angiogenesis. / Binder, Bernard Y K; Sondergaard, Claus S.; Nolta, Jan; Leach, Jonathan K.

In: PLoS One, Vol. 8, No. 12, e82134, 02.12.2013.

Research output: Contribution to journalArticle

Binder, Bernard Y K ; Sondergaard, Claus S. ; Nolta, Jan ; Leach, Jonathan K. / Lysophosphatidic acid enhances stromal cell-directed angiogenesis. In: PLoS One. 2013 ; Vol. 8, No. 12.
@article{9bda84c7d3fb4b22951d6a82eff7abc4,
title = "Lysophosphatidic acid enhances stromal cell-directed angiogenesis",
abstract = "Ischemic diseases such as peripheral vascular disease (PVD) affect more than 15{\%} of the general population and in severe cases result in ulcers, necrosis, and limb loss. While the therapeutic delivery of growth factors to promote angiogenesis has been widely investigated, large-scale implementation is limited by strategies to effectively deliver costly recombinant proteins. Multipotent adipose-derived stromal cells (ASC) and progenitor cells from other tissue compartments secrete bioactive concentrations of angiogenic molecules, making cell-based strategies for in situ delivery of angiogenic cytokines an exciting alternative to the use of recombinant proteins. Here, we show that the phospholipid lysophosphatidic acid (LPA) synergistically improves the proangiogenic effects of ASC in ischemia. We found that LPA upregulates angiogenic growth factor production by ASC under two- and three-dimensional in vitro models of serum deprivation and hypoxia (SD/H), and that these factors significantly enhance endothelial cell migration. The concurrent delivery of LPA and ASC in fibrin gels significantly improves vascularization in a murine critical hindlimb ischemia model compared to LPA or ASC alone, thus exhibiting the translational potential of this method. Furthermore, these results are achieved using an inexpensive lipid molecule, which is orders-of-magnitude less costly than recombinant growth factors that are under investigation for similar use. Our results demonstrate a novel strategy for enhancing cell-based strategies for therapeutic angiogenesis, with significant applications for treating ischemic diseases.",
author = "Binder, {Bernard Y K} and Sondergaard, {Claus S.} and Jan Nolta and Leach, {Jonathan K}",
year = "2013",
month = "12",
day = "2",
doi = "10.1371/journal.pone.0082134",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Lysophosphatidic acid enhances stromal cell-directed angiogenesis

AU - Binder, Bernard Y K

AU - Sondergaard, Claus S.

AU - Nolta, Jan

AU - Leach, Jonathan K

PY - 2013/12/2

Y1 - 2013/12/2

N2 - Ischemic diseases such as peripheral vascular disease (PVD) affect more than 15% of the general population and in severe cases result in ulcers, necrosis, and limb loss. While the therapeutic delivery of growth factors to promote angiogenesis has been widely investigated, large-scale implementation is limited by strategies to effectively deliver costly recombinant proteins. Multipotent adipose-derived stromal cells (ASC) and progenitor cells from other tissue compartments secrete bioactive concentrations of angiogenic molecules, making cell-based strategies for in situ delivery of angiogenic cytokines an exciting alternative to the use of recombinant proteins. Here, we show that the phospholipid lysophosphatidic acid (LPA) synergistically improves the proangiogenic effects of ASC in ischemia. We found that LPA upregulates angiogenic growth factor production by ASC under two- and three-dimensional in vitro models of serum deprivation and hypoxia (SD/H), and that these factors significantly enhance endothelial cell migration. The concurrent delivery of LPA and ASC in fibrin gels significantly improves vascularization in a murine critical hindlimb ischemia model compared to LPA or ASC alone, thus exhibiting the translational potential of this method. Furthermore, these results are achieved using an inexpensive lipid molecule, which is orders-of-magnitude less costly than recombinant growth factors that are under investigation for similar use. Our results demonstrate a novel strategy for enhancing cell-based strategies for therapeutic angiogenesis, with significant applications for treating ischemic diseases.

AB - Ischemic diseases such as peripheral vascular disease (PVD) affect more than 15% of the general population and in severe cases result in ulcers, necrosis, and limb loss. While the therapeutic delivery of growth factors to promote angiogenesis has been widely investigated, large-scale implementation is limited by strategies to effectively deliver costly recombinant proteins. Multipotent adipose-derived stromal cells (ASC) and progenitor cells from other tissue compartments secrete bioactive concentrations of angiogenic molecules, making cell-based strategies for in situ delivery of angiogenic cytokines an exciting alternative to the use of recombinant proteins. Here, we show that the phospholipid lysophosphatidic acid (LPA) synergistically improves the proangiogenic effects of ASC in ischemia. We found that LPA upregulates angiogenic growth factor production by ASC under two- and three-dimensional in vitro models of serum deprivation and hypoxia (SD/H), and that these factors significantly enhance endothelial cell migration. The concurrent delivery of LPA and ASC in fibrin gels significantly improves vascularization in a murine critical hindlimb ischemia model compared to LPA or ASC alone, thus exhibiting the translational potential of this method. Furthermore, these results are achieved using an inexpensive lipid molecule, which is orders-of-magnitude less costly than recombinant growth factors that are under investigation for similar use. Our results demonstrate a novel strategy for enhancing cell-based strategies for therapeutic angiogenesis, with significant applications for treating ischemic diseases.

UR - http://www.scopus.com/inward/record.url?scp=84891607163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891607163&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0082134

DO - 10.1371/journal.pone.0082134

M3 - Article

C2 - 24312635

AN - SCOPUS:84891607163

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e82134

ER -